Home > Insider Trading > Filing (0001209191-21-047263)

Filing Details

Accession Number:: 0001209191-21-047263
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-07-19 19:52:13
Reporting Period:: 2021-07-15

Accepted Time:: 2021-07-19 19:52:13
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1000694	Novavax Inc	NVAX	Biological Products, (No Disgnostic Substances) (2836)	222816046

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1342823	M Gregory Glenn	C/O Novavax, Inc. 21 Firstfield Road Gaithersburg MD 20878	President, R&D	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-07-15	550	$27.00	3,361	No	4	M	Direct
Common Stock	Acquisiton	2021-07-15	870	$27.60	4,231	No	4	M	Direct
Common Stock	Acquisiton	2021-07-15	1,105	$46.00	5,336	No	4	M	Direct
Common Stock	Acquisiton	2021-07-15	3,129	$5.95	8,465	No	4	M	Direct
Common Stock	Disposition	2021-07-15	730	$177.62	7,735	No	4	S	Direct
Common Stock	Disposition	2021-07-15	2,318	$178.19	5,417	No	4	S	Direct
Common Stock	Disposition	2021-07-15	796	$179.29	4,621	No	4	S	Direct
Common Stock	Disposition	2021-07-15	550	$180.57	4,071	No	4	S	Direct
Common Stock	Disposition	2021-07-15	560	$181.45	3,511	No	4	S	Direct
Common Stock	Disposition	2021-07-15	300	$182.38	3,211	No	4	S	Direct
Common Stock	Disposition	2021-07-15	399	$183.81	2,812	No	4	S	Direct
Common Stock	Disposition	2021-07-15	1	$184.27	2,811	No	4	S	Direct
Common Stock	Acquisiton	2021-07-15	4,823	$5.95	7,634	No	4	M	Direct
Common Stock	Disposition	2021-07-15	161	$179.14	7,473	No	4	D	Direct
Common Stock	Disposition	2021-07-15	2,253	$179.14	5,220	No	4	F	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	D	Direct
No	4	F	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-07-15	550	$0.00	550	$27.00
Common Stock	Stock Option (Right to Buy)	Disposition	2021-07-15	870	$0.00	870	$27.60
Common Stock	Stock Option (Right to Buy)	Disposition	2021-07-15	1,105	$0.00	1,105	$46.00
Common Stock	Stock Option (Right to Buy)	Disposition	2021-07-15	3,129	$0.00	3,129	$5.95
Common Stock	Stock Appreciation Right	Disposition	2021-07-15	4,823	$0.00	4,823	$5.95

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2026-11-14	No	4	M	Direct
3,131	2027-12-15	No	4	M	Direct
11,914	2028-12-13	No	4	M	Direct
56,251	2029-09-26	No	4	M	Direct
37,182	2029-09-26	No	4	M	Direct

Footnotes

The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.9859 to $177.96, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.988 to $178.9871, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.0099 to $179.9087, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $180.14 to $180.9008, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $181.1643 to $182.0783, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $182.19 to $182.5638, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $183.1998 to $184.1349, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reporting person received 2,409 shares of common stock upon the net exercise of 4,823 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 161 shares of common stock underlying the stock appreciation rights representing the base value and 2,253 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on July 15, 2021 of $179.14.
Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the November 14, 2016 grant date and the remaining seventy-five percent (75%) of the shares vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
Twenty-five percent (25%) of the shares subject to this stock appreciation right grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.